Saturday 17 October 2026
Export KRSA’s income statement to Excel — free account
Korsana Biosciences, Inc.
KRSA Healthcare Biotechnology
In the quarter to June 2026, revenue fell 43.2%, EPS fell 272.7% and free cash flow fell 184.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
32.38
1.27
−3.77%
Follow KRSA
Korsana Biosciences, Inc. (KRSA) P/E ratio
Korsana Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 10.6× (April 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| 16 more quarters | Free account |
Against its own ten years
Low 0.0×
High 10.6×
Ten-year median
0.0×
Current reading's percentile
93
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| QURE uniQure N.V. compare | n/m |
| STOK Stoke Therapeutics, Inc. compare | n/m |
| ABSI Absci Corporation compare | n/m |
| RARE Ultragenyx Pharmaceutical Inc. compare | n/m |
| MAZE Maze Therapeutics, Inc. compare | n/m |
| NTLA Intellia Therapeutics, Inc. compare | n/m |
| KRSA Korsana Biosciences, Inc. | n/m |
| IMCR Immunocore Holdings PLC Sponsored ADR compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)